□□□□□□□□□□□□□□□□□ (Recovery Kernel)

□□□□□□□□□□□□□□□□

**□□□□□□□□□□□□□□ "Recovery Kernel" (□□□□□□□□□□□□□□

**□□□□□□□□□□□: □□□□□□□□□□□□

□□□

□□□

□□□

□□□□

- □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□

□□□□

(phu chieaw chaen) **(Note: In a harm-reduction context, "junkie" is often considered stigmatizing and inappropriate. The term "" (phu chieaw chaen), which translates to "person with expertise" or "addict," is more respectful and aligned with the non-judgmental approach.)**		
(addict)		
/**	(**	# **## **: - ****:**
(DNA		

"willpower" □□ □□□□□□□□) □□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□: **- **□□□□□□□□□□:**** □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□ □□□□ □□□ □□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□ **- **□□□□□□□□□□□□□ □□□□□□□□□□□□:** □□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □**	□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□: □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ tương tác □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□: □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□	
□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□	*□□□□□□□□□□□□□□□□□□□

(treatment-resistant)		*** :**

> *

□□ (Recovery Kernel)

1. □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
- □□□□□□□□□□□□□□□□□□□□

□□□

- □□□□

2. **[illegible]**: [illegible] [illegible]
3. **[illegible]**: [illegible]

# [illegible]: [illegible] **## [illegible]?** [illegible] **"Recovery Kernel"** [illegible] **## [illegible]:** **1. **[illegible]:** - [illegible]: [illegible] - [illegible]: [illegible]	**[illegible] ([illegible])** **(Translation: [illegible] [illegible])** **- **[illegible]:** [illegible] **- **[illegible]:** [illegible] **- **[illegible]:** [illegible] **- **[illegible]**
[illegible] → [illegible] [illegible]	[illegible] ([illegible]) → [illegible] 80 [illegible]. [illegible]. [illegible]. [illegible].
Medical emergency from overdose → private hospital. Comfortable room. Addiction specialist. Insurance covers it.	Medical emergency from overdose → ER. Stabilized. Discharged in 12 hours with a pamphlet. No follow-up care.
[illegible] [illegible] (HR) [illegible] (EAP) [illegible] 3 [illegible]	[illegible] → [illegible] [illegible] [illegible]
[illegible] → [illegible] [illegible] [illegible] [illegible]	[illegible] - [illegible] - [illegible] - [illegible] - [illegible]
[illegible] [illegible] → [illegible]	[illegible] Medicaid [illegible] → [illegible]

□□□□□□□ (pharmacogenomics) □□□□□□□. □□□ □□□□□□ 2,000 □□□. □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□.	□□□□□□□□. □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□
Overdose fatality from wealthy neighborhood → news coverage. Community grief. Demand for systemic action.	Overdose fatality from poor neighborhood → brief item on page six. 'Community known for drug problems.' No action.
□□ □□□□□□□□□□□□□ (prescription opioids) □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□ □□□□□□□□□□□□□□□□□□□□ (iatrogenic) □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□ □□□□□□□□□	□□ □□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□) → □□ □□□□□ □□ □□□□□□□□□□

□□□□□□□□□□□□□□□□□□□

□□□

**□□□□□□□□□□: □□□□□□□□□□□

while preserving the emotional register and structural integrity.)
□□□□□□□□ (The Architect)

□□□□□□□□

COMT (□□□□□□□□□□□□□□), **DRD2 (□□□□□□□□ 2)**, **MTHFR (□□□□□ □□ □□□□ □□□□□)** □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ * **Blueprint (□□□□□□□□)** □□□□ □□□□□□		
□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□	□□□□□□□□□□□□□□□□ ADHD - □□□□□□□□□□ "□□□□□□□□□□□□□□□□ □□□□□□□□□□□□" (COMT □□□□□□□□ Val/Val) □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ (dopamine)□□□□□□□□ **□□□□□□□□□□:** ADHD □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ COMT Val/Val □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□ (dopamine) □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ ADHD □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□ **□□□□□□□□□□□□□□□□□□□□□□□□□□□:** 1. **□□□□□□□□□□□□□□□□□□:** □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□□□□□□□□

	□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ DNA □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□ MTHFR (Methyltetrahydrofolate reductase) □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ (Cognitive function) □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□	
□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□ (Auditory Processing Disorder) □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ COMT Worrier - **□□□□□□□□□□□:** □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ (Auditory Processing Disorder) □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ - **□□□□□□□□□□□:** □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ - **□□□□□□□□□□□□□□□□:** □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ COMT Worrier □□□□□□□□□□ □□□□	□□□□□□□□□□□□□□□□□ (depressants) □□□□ άν □□□□□□ (cannabis) □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□
□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ **(Kun talat klen wa klaw, hap lai mi yut, sai ta khon khwa mai yut thaman.)**	□□□□□□□□□□ COMT (Met/Met) - □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□□□□□□□□□□)	□□□□□□□□□□□□□□□□□□□□□ (benzodiazepine) □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□	□□□□□□□□□□□ COMT □□□□□□□ Val/Val (□□□□□□□□□□□□) □□□□□□□ □□□□□□□□□□ DRD2 A1 - □□□	□□□□□□□□□□□□□□□□□□□ (stimulants) □□□□□□□ □□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□

□□□□ □□□□

□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□

□□□□□□□□ **5:** □□□□□□□□□

- □□□□□□□□□□□□□/□□□□□□□□□□□□

□□□

□□□

□□□□□□□□□: □□□□□□□□□□

□□□ - □□□□

This phrase conveys a sense of non-dependence on someone else's approval or comprehension. The direct and concise Thai translation maintains the same meaning while reflecting a warm, supportive tone suitable for peer support contexts.

□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□

□□□

□□□□□□□ **7:** □□□□□□□□

2. **[illegible]**: [illegible]/[illegible]
[illegible] [illegible]
[illegible].

3. **[illegible]**: [illegible]
[illegible] [illegible]
[illegible].

4. **[illegible]

[illegible] (The Moral Framing Decision)

[illegible]:

[illegible]
[illegible]
[illegible] "[illegible]" [illegible] [illegible]
[illegible]
[illegible] [illegible]
[illegible]

[illegible]:

1. **[illegible]: ** [illegible]
[illegible] [illegible]
2. **[illegible]: [illegible]

[illegible] (addiction) [illegible] [illegible]
[illegible] [illegible] đạo đức [illegible],
[illegible], [illegible] — [illegible] [illegible]
[illegible] [illegible]
[illegible]

> *[illegible] [illegible]
> [illegible]
> [illegible]
> [illegible] [illegible]
> [illegible]*

[illegible]

[illegible]

[illegible]
[illegible]/[illegible]

□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □ □□□□ □□□□□□ □□□□□:

- **□□□□□□□□□□□□□□□□□□□□□□□□□□□:** □□□□□□□□□□□□□□□□□□□□

lifetime than the criminal justice, emergency medical, and social services costs of untreated addiction.

> *[illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]*

[illegible] (The Virtue of Suffering Doctrine)

[illegible]:

1. **[illegible]:** [illegible] [illegible], [illegible] [illegible]

2. **[illegible]:** [illegible], [illegible] [illegible]

3. **[illegible]:** [illegible]. [illegible]
The idea that someone must 'hit rock bottom' before they are ready to be helped is not supported by evidence. It is supported by the intuition that suffering purifies — a remnant of moral punishment frameworks — and by the practical usefulness of delaying expensive treatment until the crisis has resolved itself through mortality.

> *[illegible] [illegible] [illegible] [illegible]*

[illegible]: [illegible]

[illegible]:

1. **[illegible]:** [illegible] [illegible] [illegible]

2. **[illegible]:** [illegible] [illegible] [illegible] [illegible]

3. **□□□□□□□□□□□□□□□□□□□□□□:** □□□□□□□□□□□□□□□□□□□□

□□□□□□□□ 8: □□ (Self-Regulation)

1. **□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□□

□□□

□□□□□□□□□□□□□□□□
□□□□□□□□□□□

**4. **□□□□□□□□□□□□□□
(Initiation)****
- □□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□
□□□□□
- □□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□
□□□□□□□□

**5. **

□□□□□□□□ **1-2**	□□□□□□□□□□□□□□□□□□□□

	□□□□

□□□

□□□

□□□

(This information is a tool for recovery and support for individuals going through the process of withdrawal or loss of resilience.)	"Recovery Kernel" ок *Recovery Kernel* **1. **: **2. **: **3. **: (	
(neurotransmitter)	**(Brain Chemical)** **(Neurotransmitter)**	, , ,
(dopamine)	"" **(go get it)** "" **(Naloxone)** **(opioids)**	
(GABA)	**(Krabwan kaewd hun thong samruttaphap chit)** **1. **:** ""	

□□□□□□□□ "□□□ □□□□□□□□□□□□□ □□□□□□□□□" □□□ □□□□□□□□ □□□□□□□□□□ **GABA** □□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□	**2.** **□□□□□□□□□□□□□□□□□□□□:** □□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

1. **□□□□□□ GABRA2: □□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ **GABRA2** □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□ **2. **□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□:** □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□		
□□□□□□□□□□□□□□□□ □□□□ **(Pharmacogenomics)** □□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□ **(DNA)** □□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□	□□□□□□□□□□□□□□□□

□□□□□ □□□ □□□□□

(treatment-resistant)		
□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□ "□□□ □□□□□□□□□□□□□ □□□□□□" □□□□□□ □□□□□□□□□□□ - **□□□□□□□□□□□ □□□□□□□□□□:** □□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□ □□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ - **□□□□□□□□□□ □□□□□□□□□□□:** □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□ - **□□□□□□□□□ □□□□:** □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

□□□□□□

(Likh sud phâp khwân thāi māi chān găt □□□ nī pen làk pradak CC0 thang chi'n sōt ai dâi sùd)

Crisis: call or text 988 · Emergency: 911 · Free resources: archive.org/details/the-recovery-kernel